Global Thorium-227 Market Strategic Research Report

Scope of the Report

The global Thorium-227 market size is predicted to grow from US$ 104 million in 2025 to US$ 229 million in 2032; it is expected to grow at a CAGR of 12.1% from 2026 to 2032.

In 2025, global production of Thorium-227 is approximately 163 grams, with a global average market price of around $650,000 per gram. The total global production capacity for Thorium-227 in 2025 is approximately 320 grams. The average gross profit margin for the industry stands at 84%. Thorium-227 (Th-227) is an artificially produced radioactive actinide isotope of thorium, with an atomic number of 90 and a mass number of 227. It is mainly generated through decay chains involving heavy radioactive elements such as radium and actinium, and can also be produced through artificial nuclear reactions. Thorium-227 has a half-life of approximately 18.7 days and emits high-energy alpha particles, making it a valuable isotope for modern nuclear medicine applications. Due to the strong cell-killing capability and limited tissue penetration range of alpha radiation, Thorium-227 is considered an important candidate radionuclide for Targeted Alpha Therapy (TAT).

The upstream segment of the Thorium-227 supply chain includes radioactive isotope sources, nuclear material production facilities, radiochemical preparation technologies, and nuclear-grade analytical equipment suppliers. Since Thorium-227 has extremely limited natural availability and a relatively short half-life, it cannot be obtained directly from conventional mineral resources and must be produced through radioactive decay chains or artificial nuclear reactions. The upstream sector involves parent radionuclide materials, actinide-related resources, nuclear reactors or accelerators, radiochemical separation systems, and high-precision radioactive analysis equipment. Isotope production also requires strict nuclear safety compliance, including radioactive material licensing, radiation protection infrastructure, and specialized transportation systems. Global Thorium-227 production capabilities remain limited and are concentrated among advanced nuclear research institutions, isotope producers, and nuclear medicine development platforms. The midstream segment of the Thorium-227 industry mainly includes isotope producers, nuclear medicine research organizations, and radiopharmaceutical developers. This stage involves Thorium-227 production, purification, quality control, radiolabeling technology development, and conjugation with targeted carriers to create radiopharmaceutical candidates. Since Thorium-227 is typically combined with antibodies, peptides, or other targeting molecules, the midstream industry requires capabilities in radiopharmaceutical chemistry, conjugation technologies, and preclinical development. Currently, Thorium-227-based products remain largely in research and clinical development stages, with limited commercial supply. Several international pharmaceutical companies and nuclear medicine developers are advancing Thorium-227-based targeted alpha therapy programs, supporting the transition of this isotope from research material toward clinical applications. The downstream applications of Thorium-227 are mainly focused on cancer treatment, radiopharmaceutical development, and nuclear medicine. Targeted alpha therapy is considered one of the most promising application areas, particularly for hematological cancers, solid tumors, and difficult-to-treat cancers. Compared with conventional radiation therapy, alpha particles have high linear energy transfer (LET), allowing them to deliver strong cytotoxic effects within a short range and enabling highly precise treatment approaches. Thorium-227 is also used in nuclear medicine research, drug target validation, and clinical development programs. With increasing global demand for advanced cancer therapies, growth of precision medicine, and commercialization of radiopharmaceuticals, Thorium-227 is expected to become an important radionuclide in the future targeted alpha therapy market.

As the global number of cancer patients rises and precision medicine technologies advance, radiopharmaceutical therapy is emerging as a key direction in oncology. Targeted Alpha Therapy (TAT) has garnered significant attention from pharmaceutical companies and nuclear medicine research institutions due to the unique properties of alpha particles, including high linear energy transfer (LET), a short range of action, and potent tumor-killing capabilities. Thorium-227, an alpha-emitting therapeutic radionuclide, can be conjugated with targeting vectors—such as antibodies, peptides, or small-molecule ligands—to form Targeted Thorium Conjugates (TTCs), enabling the precise destruction of specific tumor cells. With the maturation of TAT technology and ongoing clinical research, Thorium-227 has demonstrated substantial potential in treating both hematological malignancies and solid tumors, positioning itself as a pivotal radionuclide driving the growth of the radiopharmaceutical industry.

Another major driver of Thorium-227 industry development is the establishment of a global radiopharmaceutical supply chain. As targeted radiopharmaceutical therapy transitions from the research stage to clinical development, a stable supply of high-quality therapeutic radionuclides has become critical to industry growth. Thorium-227 is typically derived from the Actinium-227 decay chain and isolated via radiochemical processes; the supply chain encompasses nuclear reactors, isotope separation technologies, radiopharmaceutical manufacturing platforms, and specialized transportation systems. Given the stringent requirements for purity, radioactivity, and supply stability associated with therapeutic-grade radionuclides, future industry competition will hinge not only on production capacity but also on the ability to ensure large-scale supply and maintain quality control systems that meet medical standards. As global investment in alpha-radionuclide therapy research increases, the development of production and supply capabilities for Thorium-227 will become a key strategic focus for the industry.

In recent years, major pharmaceutical and biotechnology companies have steadily increased their investment in radiopharmaceuticals and nuclear medicine, propelling Thorium-227 from a material used in basic research toward becoming a potential commercial therapeutic product. Compared to some traditional alpha-emitting radionuclides, Thorium-227 offers the advantage of being able to form chelated bonds with targeting molecules, facilitating the development of therapies tailored to various tumor targets. Research into Thorium-227 targeting markers such as HER2, PSMA, CD22, and Mesothelin is currently underway, laying the technical foundation for expanding its future applications. With the accumulation of clinical trial data, advancements in companion diagnostic technologies, and the widespread adoption of precision therapy models, Thorium-227 is poised to address a broader range of cancer treatment scenarios and drive further expansion of the radiopharmaceutical market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Thorium-227 market?

What factors are driving Thorium-227 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Thorium-227 market opportunities vary by end market size?

How does Thorium-227 break out by Type, by Application?

This report presents a comprehensive overview of the global Thorium-227 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• High-specific Activity
• Low-specific Activity

Segment by Nuclear State

• Thorium-227 Ground State
• Thorium-227 Decay Chain Products

Segment by Purity Grade

• Research Grade Thorium-227
• High Purity Thorium-227
• Pharmaceutical Grade Thorium-227

Segment by Production Source

• Actinium-227 Derived Thorium-227
• Reactor/Accelerator Produced Thorium-227

Segment by Application

• Scientific Research
• Cancer Treatment

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Thorium-227 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Scientific Research, Cancer Treatment evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact